Novocure's PANOVA-3 Phase 3 trial meets primary endpoint in pancreatic cancer; plans regulatory filings

NovoCure Ltd

PANOVA-3 met primary endpoint: mOS 16.20 months (TTFields) vs 14.16 months (control), HR=0.819, p=0.039 (N=571).
Survival rate benefit increased over time: 13% improvement at 12 months, 33% improvement at 24 months.
TTFields therapy was well-tolerated; safety consistent with prior studies.
Novocure plans regulatory filings in U.S., EU, Japan, and other key markets based on PANOVA-3.
This is Novocure's third positive Phase 3 trial in two years; full results at upcoming congress.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.